The lancet oncology
-
The lancet oncology · Jul 2022
Multicenter StudyEffect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study.
Few studies have evaluated the effect of glucose concentrations on cancer prognosis. We investigated the association between haemoglobin A1c (HbA1c) concentrations and survival in patients with oral squamous cell carcinoma. ⋯ Kaohsiung Chang Gung Memorial Hospital, Taiwan (grant numbers CFRPG8K0131 and CORPG8L0481).
-
The lancet oncology · Jul 2022
Randomized Controlled Trial Multicenter StudyUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer. ⋯ GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche.
-
The lancet oncology · Jul 2022
Multicenter StudyMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study.
Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. ⋯ Insightec and the National Cancer Institute.
-
The lancet oncology · Jul 2022
Multicenter StudyAberrant circulating tumour DNA methylations as biomarkers for early detection of pancreatic ductal adenocarcinoma: a retrospective study.
Pancreatic ductal adenocarcinoma is a cancer with high mortality and low survival, the early detection of which is hampered by the absence of specific symptoms until an advanced stage is reached. No reliable early screening tool for pancreatic ductal adenocarcinoma is currently available. Circulating tumour DNA (ctDNA) methylation has emerged as a promising new type of biomarker for blood-based early detection of multiple types of cancer. As a part of the PanSeerX study, which aims to discover robust ctDNA methylation markers for multicancer early screening, a customised pancreatic ductal adenocarcinoma-specific targeted methylation sequencing panel has been preliminarily developed and validated for its accuracy in classifying pancreatic ductal adenocarcinoma from retrospective clinical plasma samples. ⋯ The National Key Research and Development Project of China (grant 2019YFC1315904), the 234 Discipline Climbing Plan Project of the First Affiliated Hospital of Naval Military Medical University (grant 2019YXK033), and the Shanghai Science and Technology Committee.
-
The lancet oncology · Jul 2022
Multicenter StudyCatastrophic expenditure and treatment delivery outcomes in patients with colorectal cancer in India: a prospective, multicentre cohort study.
Little is known about the factors preventing patients with colorectal cancer in India from receiving the treatment they need to reach the best oncological outcomes. Patients often struggle to pay for cancer care, possibly leading to treatment dropout. The aim of this study was to assess treatment adherence and catastrophic expenditure rates in a cohort of patients with colorectal cancer in India. ⋯ National Institute for Health Research Global Health Research Unit Grant (NIHR 16.136.79) with aid from the UK Government to support global health research.